EYEPOINT PHARMACEUTICALS INC (EYPT)
US30233G2093 - Common Stock
EYPT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While EYPT has a great health rating, there are worries on its profitability. EYPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year EYPT has reported negative net income.
In the past year EYPT had a positive cash flow from operations.
EYPT had negative earnings in each of the past 5 years.
EYPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
EYPT has a Return On Assets of -19.93%. This is in the better half of the industry: EYPT outperforms 61.54% of its industry peers.
The Return On Equity of EYPT (-26.58%) is better than 69.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.93% | ||
| ROE | -26.58% | ||
| ROIC | N/A |
ROA(3y)-32.93%
ROA(5y)-45.22%
ROE(3y)-54.78%
ROE(5y)-218.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 89.92%, EYPT belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
In the last couple of years the Gross Margin of EYPT has grown nicely.
The Profit Margin and Operating Margin are not available for EYPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.68%
GM growth 5YN/A
2. Health
2.1 Basic Checks
EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EYPT has been increased compared to 1 year ago.
Compared to 5 years ago, EYPT has more shares outstanding
EYPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
EYPT has an Altman-Z score of 1.40. This is a bad value and indicates that EYPT is not financially healthy and even has some risk of bankruptcy.
EYPT has a Altman-Z score of 1.40. This is in the better half of the industry: EYPT outperforms 64.10% of its industry peers.
EYPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.4 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 5.45 indicates that EYPT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.45, EYPT is in the better half of the industry, outperforming 71.28% of the companies in the same industry.
EYPT has a Quick Ratio of 5.39. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EYPT (5.39) is better than 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.39 |
3. Growth
3.1 Past
EYPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.97%, which is quite impressive.
Looking at the last year, EYPT shows a quite strong growth in Revenue. The Revenue has grown by 11.15% in the last year.
Measured over the past years, EYPT shows a very strong growth in Revenue. The Revenue has been growing by 73.11% on average per year.
EPS 1Y (TTM)32.97%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q71.55%
Revenue 1Y (TTM)11.15%
Revenue growth 3Y10.14%
Revenue growth 5Y73.11%
Revenue growth Q2Q33.22%
3.2 Future
The Earnings Per Share is expected to grow by 14.45% on average over the next years. This is quite good.
Based on estimates for the next years, EYPT will show a very strong growth in Revenue. The Revenue will grow by 55.32% on average per year.
EPS Next Y-8.38%
EPS Next 2Y-18.69%
EPS Next 3Y-14.58%
EPS Next 5Y14.45%
Revenue Next Year-7.58%
Revenue Next 2Y-46.98%
Revenue Next 3Y-58.7%
Revenue Next 5Y55.32%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
EYPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EYPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EYPT's earnings are expected to decrease with -14.58% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.69%
EPS Next 3Y-14.58%
5. Dividend
5.1 Amount
EYPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EYEPOINT PHARMACEUTICALS INC
NASDAQ:EYPT (5/7/2024, 5:52:07 PM)
After market: 11.84 -0.03 (-0.25%)11.87
+0.67 (+5.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap618.19M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.93% | ||
| ROE | -26.58% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.92% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)32.97%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-8.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.15%
Revenue growth 3Y10.14%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y